Chemoradiotherapy for Advanced Esophageal Cancer (PaRCUS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02297217|
Recruitment Status : Recruiting
First Posted : November 21, 2014
Last Update Posted : April 4, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Esophageal Cancer||Drug: Carboplatin and Taxol (paclitaxel) Radiation: External Beam Radiation||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase 2 Study of Palliative Chemo-Radiotherapy With Carbo-Taxol in Non-Curative Cancer of the Esophagus|
|Actual Study Start Date :||November 21, 2019|
|Estimated Primary Completion Date :||April 30, 2024|
|Estimated Study Completion Date :||April 30, 2025|
Experimental: Chemotherapy with Concurrent Radiation
Carboplatin and paclitaxel will be administered intravenously on Days 1 and 8 while radiation therapy is administered
Drug: Carboplatin and Taxol (paclitaxel)
Patients will receive carboplatin (AUC 2) and paclitaxel (50 mg/m2) intravenously on Days 1 and 8. Patients are seen for 2 weekly Treatment Visits during concurrent chemo-radiation then every 28 days until the End of Study Visit, approximately 6 months after Treatment Visit 1. Preparation and administration of chemotherapy will be according to local site standard of care.
Radiation: External Beam Radiation
Patients will receive external beam radiation therapy of 30Gy/10 fractions over two weeks (or reduced to 25 Gy/10 fractions if acute toxicity parameters are met during the run-in) and receive carboplatin (AUC 2) and paclitaxel (50 mg/m2) intravenously on Days 1 and 8. Treatment will be planned, prescribed and delivered using standard 3D radiotherapy planning techniques to encompass the primary tumor and surrounding clinical target volume. Patients are seen for 2 weekly Treatment Visits during concurrent chemo-radiation then every 28 days until the End of Study Visit, approximately 6 months after Treatment Visit 1.
- Proportion of patients who achieve relief of dysphagia [ Time Frame: up to day 85 ]Will be measured as the proportion of patients who achieve relief of dysphagia, defined as improvement of at least one point on the Mellow Dysphagia Score, measured at Day 57 after the start of radiotherapy, and maintained for at least 28 calendar days (until the Day 85 visit).
- Dysphagia progression free survival [ Time Frame: 6 Months ]
Will be measured from screening to the time of first progression of dysphagia. Progression of dysphagia will be defined as follows:
- A drop of at least 1 point on the 5 point Mellow Dysphagia Score,
- Stricture requiring intervention, or
Other secondary objectives as follows:
Time to achieving any response in dysphagia after treatment as measured by an improvement of at least 1 point on the 5 point Mellow Dysphagia Score. Number of patients receiving secondary treatment (radiation, chemotherapy or stenting), Utility assessments pre to post treatment and at 3 and 6 months, Quality of life differences post treatment and at 3 and 6 months. Measures of biological/serological correlates of response, Acute and late toxicity.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Biopsy proven carcinoma of the esophagus.
- Not a candidate for radical/curative treatment due to the advanced nature of the disease, presence of metastases, or intercurrent illness.
- Symptomatic patients with Mellow Dysphagia Scores of ≥ 1 i.e. able to eat only some solids.
- ECOG Performance status ≤ 2.
- Patients able to begin treatment within 14 days of signing the informed consent form.
- Patient is at least 18 years old.
Hematological function as defined by the following laboratory parameters:
- Hemoglobin > 100g/L
- Platelet count > 100x10E9/L
- Absolute neutrophil count > 1.5x10E9/L
Renal function to undergo chemotherapy as defined by the following laboratory parameters:
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5x the upper limit of institutional normal (≤ 5 if liver metastases)
- Total bilirubin ≤ 1.5x the upper limit of institutional normal
- Calculated creatinine clearance ≥ 50 mL/min using the Cockcroft-Gault formula
- Patients capable of childbearing are using adequate contraception.
- Written and informed consent of patient.
- Previous radiotherapy delivered to the chest.
- Synchronous active malignancies.
- Pregnant or lactating patients: women of child bearing potential must have a negative serum pregnancy test within 7 days of Treatment Visit 1. Women or men of child bearing potential must use effective contraception (defined by the use of two birth control methods, which can be either two barrier methods or a barrier method plus a hormonal method to prevent pregnancy). Subjects must start using birth control from the time they have signed the Informed Consent Form prior to start of therapy until 120 days post completion of study therapy or study discontinuation, which must be documented in the eCRF.
- Patients unfit for any treatment component, including absolute contraindications for radiotherapy or Connective Tissue Disease.
- Tracheo-esophageal fistula.
- Esophageal stents in situ.
- Previous chemotherapy for esophageal cancer
- Unable to complete surveys in English without aid of interpreter.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02297217
|Contact: Marc Kerba, MD||403 521 firstname.lastname@example.org|
|Contact: Amy Abelemail@example.com|
|Tom Baker Cancer Centre||Recruiting|
|Calgary, Alberta, Canada, T2N 4N2|
|Contact: Marc Kerba, MD 403-521-3164 firstname.lastname@example.org|
|Contact: Amy Abel Amy.Abel@ahs.ca|
|Principal Investigator:||Marc Kerba, MD||403 521 3164|
|Responsible Party:||Marc Kerba, MD, AHS Cancer Control Alberta|
|Other Study ID Numbers:||
|First Posted:||November 21, 2014 Key Record Dates|
|Last Update Posted:||April 4, 2022|
|Last Verified:||March 2022|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Digestive System Neoplasms
Neoplasms by Site
Head and Neck Neoplasms
Digestive System Diseases
Antineoplastic Agents, Phytogenic
Molecular Mechanisms of Pharmacological Action